胰岛素泵联合罗格列酮钠强化治疗2型糖尿病的临床探讨

Clinical study of continuous subcutaneous insulin infusion combined with rosiglitazone sodium in the intensive treating of type 2 diabetes mellitus

目的采用胰岛素泵(CSⅡ)联合罗格列酮钠强化治疗2型糖尿病,评价其临床疗效。方法将75例2型糖尿病患者随机分为胰岛素泵联合罗格列酮钠治疗(CSⅡ+罗格列酮钠)组22例,单纯胰岛素泵治疗(CSⅡ)组20例、多次皮下注射胰岛素治疗(MD I)组33例,均连续治疗2周。比较三组治疗前后体重、血糖、糖化血红蛋白、空腹胰岛素、C肽、胰岛素用量、血糖达标时间、低血糖发生率及胰岛素抵抗指数(HOMA-IR)、胰岛素敏感指数(IAI)。结果胰岛素泵联合罗格列酮钠治疗组胰岛素用量最少,HOMA-IR降低最明显,IAI明显增加,低血糖发生率低,体重增加不明显。结论胰岛素泵联合罗格列酮钠强化治疗2型糖尿病,在有效控制血糖的同时节约胰岛素用量,减轻胰岛素抵抗。

Objective To evaluate the effect of continuous subcutaneous insulin infusion（ CSⅡ ） combined with rosiglitazone sodium on type 2 diabetic patients. Methods 75 patients with type 2 diabetes mellitus（T2DM） were divided into 3 groups randomly：CS Ⅱ combined with rosiglitazone sodium （ n = 22） ; simple CS Ⅱ （ n = 20） ; multiple deliver insulin （MDI） （ n = 33 ）. The lcves of blood glucose, HbA1C, therapeutic time, amount of insulin, Fins, C -P, body weight, HOMA-IR and IAI were compared among them before and after 2 weeks of treatment. Results After treatment, compared with multiple deliver insulin group and simple CS Ⅱ group, the CS Ⅱ combined with rosiglitazone sodium group had lower levels of insulin amount and body weight, showed the decreased HOMA-IR and increased IAI. Conclusions CS Ⅱ combined with rosigitasone sodium can improve the blood glucose and insulin resistance obviously.